| Drug Class | Generic/Trade Company Names | Indication | Approving Regulatory Agency |
| Antiacne Agent | Clindamycin Foam 1% Evoclin® Connetics | Approved for topical application in the treatment of acne vulgaris | US FDA |
| Antibacterial Agent | Cefdinir Oral Suspension Omnicef® Abbott Laboratories | A new 250mg/5ml dosing option approved for use in pediatric patients 6 months to 12 years of age. This more concentrated form allows parents to administer fewer teaspoons/ dose to their children. | US FDA |
| Clindamycin Evoclin® Foam 1% Connetics | Approved for the treatment of mild-tomoderate acne vulgaris. Evoclin® was formerly referred to as Actiza™. | US FDA | |
| Antihistamine | Desloratadine Syrup CLARINEX® Schering-Plough | Approved for the relief of symptoms associated with seasonal allergic rhinitis in children >2 years of age, and perennial allergic rhinitis and chronic idiopathic urticaria, or hives of unknown cause in children as young as 6 months of age. | US FDA |
| Antipruritic Agent | Cetirizine HCl Zyrtec® Pfizer/UCB Pharma | A new chewable formulation approved for the treatment of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria in children >2 years of age. | US FDA |
| Antipsoriatic Agent | Alefacept Amevive® Biogen Idec | Approved for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. | Israeli Ministry of Health Therapeutic Goods Administration— Australia TPP Canada |
| Efalizumab Raptiva® Serono | Approved for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis. | Swissmedic CHMP Europe | |
| Etanercept Enbrel® Amgen/Wyeth Pharmaceuticals | Approved for the treatment of moderate-tosevere plaque psoriasis who failed to respond to, or have a contraindication to, or are intolerant of other systemic therapy. | US FDA CHMP Europe | |
| Dermal Filler | Hyaluronic Acid Filler Hyalite™ Mentor | Approved for soft tissue augmentation in the correction of wrinkles and folds and for lip enhancement. | CHMP Europe |
| Hyaluronic Acid Filler RESTYLANE® Medicis | Approved for the correction of moderate-tosevere facial wrinkles and folds. | US FDA | |
| Hylan-B Gel Hylaform Inamed/Genzyme | Approved for injection into the mid-to-deep dermis for correction of moderate-to-severe facial wrinkles and folds. | US FDA | |
| Injectable Poly-L-Lactic Acid Sculptra Dermik Laboratories | Approved for the correction of lipoatrophy in people with HIV infection. | US FDA | |
| Enzyme Replacement Therapy | Agalsidase Alfa Replegal™ Transkaryotic Therapies | Approved for the treatment of Fabry disease under its Notice of Compliance with Conditions Policy, under which Transkaryotic Therapies can market this product while conducting post-marketing studies | TPP Canada |
| Immunomodulatory Agent | Imiquimod Cream 5% Aldara® 3M Pharmaceuticals | Approved for clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. | US FDA TPP Canada |
Imiquimod Cream 5% | Approved for the treatment of biopsyconfirmed, primary superficial basal cell carcinoma in adults with normal immune systems. | US FDA TPP Canada | |
| Medical Device | Clinical Phototherapy System ClearTouch™ Light Unit Assembly Radiancy | Approved for the treatment of pustular inflammatory acne. | US FDA |
| Ultrasonic Skin Permeation Device SonoPrep® Sontra Medical | Approved for use with topical lidocaine. | US FDA | |
| Monoclonal Antibody | SGN-30 Seattle Genetics | Granted Orphan Drug Designation for the treatment of T-cell lymphomas. | US FDA |
| Neurotoxin | Botulinum Toxin – Type A BOTOX® Allergan | Additional indication approved for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical agents. | US FDA |
| Oncologic Agent | MDX-010 Medarex | Granted Orphan Drug Designation for the treatment of high-risk Stage II, Stage III, and Stage IV melanoma. | US FDA |
| Psoriatic Arthritis Agent | Leflunomide Arava® Aventis | A new indication approved for the treatment of adult patients with active psoriatic arthritis. | CHMP Europe |
| Etanercept Enbrel® Amgen/Wyeth Pharmaceuticals | Approved for the treatment of psoriatic arthritis. | ||
| Etanercept Enbrel® Amgen/Wyeth Pharmaceuticals | New dosing formula approved for the treatment of psoriatic arthritis and moderateto- severe plaque psoriasis – a prefilled syringe that will eliminate the need to mix the drug prior to injecting and will allow most patients receiving this drug to take only one injection/week instead of the two 25mg injections currently used weekly by patients. | US FDA | |
| Infliximab REMICADE® Schering-Plough/Centocor | Approved for use in combination with methotrexate for the treatment of active and progressive psoriatic arthritis in patients who have responded inadequately to diseasemodifying antirheumatic drugs. | CHMP Europe |
